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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not high
dose radioactive iodine-131 is more effective than low dose iodine-131 in the therapy of patients
with hyperthyroidism.
STUDY DESIGN: The review included three primary English language studies that were peer
reviewed articles published in 2003, 2010 and 2011.
DATA SOURCES: This paper evaluates three randomized control trials (one prospective
randomized and two comparative randomized) looking at the effectiveness of high dose and low
dose radioactive iodine-131 for the treatment of hyperthyroidism.
OUTCOMES MEASURED: Each study examined patients being treated with high or low dose
radioactive iodine-131. The outcomes measured include 1) incidence of failed treatment that
required further therapy 2) patients that maintained a euthyroid state 3) patients needing therapy
for hypothyroidism caused by the radioactive therapy. The measurements were evaluated with
laboratory values as well as a 5- point scoring system and clinical symptoms of hyperthyroidism
and hypothyroidism. Statistical evaluation is based on p-values and NNT.
RESULTS: Three randomized controlled trials were included in this review. Results from Leslie
et al. 2003, found that low dose regimen is as effective as high dose regimen. The conclusion and
statistical analysis of Pusuwan et al. 2011, found that high dose regimen would be more effective
than low dose regimen. Lastly, the Thientunyakit et al. 2010, study found that neither dose
regimen was shown to be more effective in the treatment of hyperthyroidism.
CONCLUSION: All three of the randomized trials in this EBM review contradicted findings in
the other. That being said, at this time there is no conclusive evidence to support whether high or
low dose radioactive iodine regimen is more effective in the treatment of hyperthyroidism. There
has to be continued research and development in this field of study to better determine a dose
regimen that is effective in managing patients with this disease.
KEY WORDS: Iodine-131, Hyperthyroidism, Comparison, Treatment
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INTRODUCTION
Radioactive iodine was introduced as a means for treatment of hyperthyroidism in 1941
by Hertz and Roberts in the United States.1 Radioactive iodine treatment has since been widely
accepted as the gold standard for treatment of hyperthyroidism for over 50 years and is preferred
over surgery or anti-thyroid medications.1 This form of therapy is primarily for patients that are
in a hyperthyroid state and have medical complications associated with it or are symptomatic
from this state. This form of treatment is relatively safe, simple and effective, but there still is a
great deal of controversy surround the amount of radiation that the patient should receive to
reach maximum efficacy. 2 The different theories for most effective dosing ranges from low dose
verses high dose regimens. The dose regime is attained from calculated doses or fixed doses of
iodine-131. With regards to low dose the treatment theory is to maintain a euthyroid state at least
one year.1,2,3 High dose theory is to induce a state of hypothyroidism followed by hormone
replacement maintenance. Calculations to determine the dose regimen takes into account gland
size, presence of nodularity and results of a radioactive iodine uptake and scan.3 Another
controversial theory is that of a fixed dose. This is when an institution uses a fixed dose method
and treats everyone with the same dose no matter the severity of their hyperthyroidism. Another
issue with deciding which method to use is that there is only about a 60% predictive rate for
estimating euthyroidism in a patient receiving iodine-131 treatment.2,3 In the United States, the
use of iodine-131 at a therapeutic level requires careful planning and patient education in regards
to protecting the public from potentially harmful ionizing radiation that is released and excreted
from the body.
Hyperthyroidism is a disease state characterized by excessive production of thyroid
hormones T3 and T4 by the thyroid which causes an increase in metabolic activity of the body.
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It is estimated that about 3% of the world’s population is affected by hyperthyroidism.3 This can
be measured with TSH and T3/T4 measurements and symptom profiles of patients.
Hyperthyroidism can be broken up into primary, secondary and tertiary forms. The classification
of the disease state is determined by the anatomical location of where the hyperthyroid state
originates. It is estimated that about 60-80% of primary hyperthyroidism is associated with
Graves’ disease.2 Hyperthyroidism may be associated with any age, sex and race. However, it is
most common in women over the age of 60.1 Symptom profiles used to diagnose
hyperthyroidism include fatigue, tremor, palpitations, diaphoresis, exophthalmos, increased
appetite and weight loss. An increase of thyroid hormone can also exacerbate comorbidities
especially cardiac in nature which can be fatal if left untreated.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not high dose
radioactive iodine-131 is more effective than low dose iodine-131 in the therapy of patients with
hyperthyroidism.
METHODS
Randomized control studies were selected on the basis of comparison of high verses low
dose of radioactive iodine-131. The studies included subjects who presented with
hyperthyroidism to the institution conducting the trial. The exclusion criteria included pregnant
patients, patients that randomly converted to euthyroidism, patients lost to follow up, children
less than 18 years old, patient refusal, physician refusal or patients previously treated with
iodine-131.1,2,3 The outcomes measured in these studies included persistent/recurrent
hyperthyroidism, sustained euthyroidism and advancement to hypothyroidism.1,2,3 Treatment
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success was considered sustained euthyroidism or induced hypothyroidism. Under these criteria,
there were three randomized controlled comparative trials that were identified and included in
this evidence based review.
An extensive search utilizing PubMed and CINAHL was completed using the key words
of “iodine-131”, “hyperthyroidism”, “comparison” and “treatment” to select relevant articles.
All of the articles utilized in this review were published in peer reviewed journals and printed in
English. The studies were also selected based on relevance and importance of the outcomes to
the patient (POEMs). The included studies were RCTs that were published in 2003, 2010 and
2011 with participants that were diagnosed with hyperthyroidism and underwent radioactive
iodine-131 therapy. Exclusion criteria included: pregnancy, patients who randomly converted to
euthyroidism, patients lost to follow up, children less than 18 years of age, patients that had a
prior treatment with radioactive iodine-131 and patient or physician refusal. The summary of the
statistical data was reported as p-values and NNTs.
Table 1. Includes the demographics of the patients included in the RCTs.
Study
Type
#
Age
Inclusion Criteria
Exclusion
Pts
Criteria
Pusuwan et
Prospective
145 41 +/Patients referred to
Patients
al.
RCT
14
the Division of
younger than
(2011)
years
Nuclear Medicine
18 years old.
Faculty of Medicine Pregnancy or
Siriraj Hospital who lactating
had not yet received patients.
radioactive iodine
Previously
treatment-naïve
treated with
patients.
iodine-131 or
surgery.
Patients
refusing
treatment.
Patients lost to
follow up.

W/D

Interventions

5

High dose vs.
Low dose
iodine-131
therapy.
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Thientunyakit
et al.
(2010)

Comparative
evaluation
RCT

144

41 +/14
years

All Hyperthyroid
patients referred to
the Nuclear
Medicine
Department,
Songklanagarind
University.

Leslie et al.
(2003)

Prospective
RCT

88

41 +/14
years

All patients being
referred to the
Nuclear Medicine
Department at St.
Boniface General
Hospital for first
treatment of Grave’s
Disease
hyperthyroidism.

Patients that
had previously
been treated
with
radioactive
iodine. Eleven
were excluded
due to loss of
follow up. Five
became
euthyroid
before
treatment.
Patient
preference for
same day
therapy.
Patients from
remote
locations.
Patient or
physician
refusal.
Patients that
were treated
with iodine131 prior.

16

Calculated vs.
Estimated
high and low
dose iodine131 therapy.

0

Low-adjusted
dose vs. Highadjusted dose.

OUTCOMES MEASURED
The outcomes measured were patient-oriented evidence that matters (POEMS). To help
measure subjective data, several clinical assessments were used to measure the outcome of the
RCTs. Thientunyakit et al. 2010, managed this by evaluating a 5-point scoring system of clinical
presentation for hyperthyroidism, symptomatic profile of fatigue, tremor, palpitations,
diaphoresis, gland size or exophthalmos.3 Reversely a 5-point clinical scoring system for
hypothyroidism post- treatment included swelling, bloating, constipation and cold sensation.3
Hypothyroidism and hyperthyroidism symptoms were then correlated with biochemical
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laboratory measurements of TSH and T3/T4. Leslie et al. 2003, evaluated physical exam and
clinical symptoms most notably gland size and ophthalmopathy, and correlated symptomatology
with biochemical laboratory examination. Pusuwan et al.2011, utilized a clinical evaluation of
cardiac complications, glandular size and goiter, nausea and thyroiditis to monitor patients pre
and post therapy.1 These clinical evaluations were also compared and correlated with
biochemical TSH and T3/T4 levels.
RESULTS
Three comparative RCTs were evaluated with patients undergoing treatment with
radioactive iodine -131. The comparative evaluation was based on high dose iodine and low dose
iodine. All studies utilized similar processes with slight variations in each study. The three
studies have similar inclusion and exclusion criteria (see Table 1 above). All studies used nuclear
medicine departments and certified physicians to conduct the therapy process.1,2,3 This provided
maximum safety and accuracy when calculating or estimating treatment doses. Follow up was
conducted by trained personnel to ensure patient safety.
Note that all of the studies that were evaluated contained dichotomous data. Statistical
calculations used included numbers needed to treat (NNT) and p-values.
The study performed by Leslie et al.2003, compared radioactive iodine-131 doses in the
treatment of Graves’ Disease. Patients were first stratified based on their radioactive iodine
uptake at four hours and were then randomized into one of four groups (high-fixed, low-fixed,
high-adjusted and low-adjusted). Only high and low-adjusted dose arms of the study were
examined in this review. A total of 43 patients were examined (low-adjusted, n=22; high
adjusted n=21) and completed the study.2All of the patients in the stratified group received the
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same therapy. The low-adjusted group received a dose of 2.96 MBq (megabequerel) (80
µCi(microcurie))/g of thyroid tissue adjusted for 24-hour uptake percentage.2 The high-adjusted
group received 4.44 MBq (120 µCi)/g of thyroid tissue adjusted for 24-hour uptake percentage.2
Most patients received antithyroid medication before treatment. This medication was
discontinued 5 days prior to therapy. Systemic beta-blockers were not discontinued during
therapy for cardiac protection.2 Patients were then examined to evaluate if they failed therapy and
remained hyperthyroid or if therapy was successful and they converted to hypothyroid or
remained euthyroid. Evaluation consisted of clinical evaluation of symptoms with physical
exam and biochemical laboratory evaluation.2 The study also has a result of a NNT of 17.
Table 2. Created from Leslie et al. 2003 Table 3.
P-value= 0.05

Low-adjusted

High-adjusted

Hyperthyroid

4 (18%)

5 (24%)

Euthyroid

0 (0%)

4 (19%)

Hypothyroid

18 (82%)

12 (57%)

Totals

22 (100%)

21 (100%)

The study by Thientunyakit et al. 2010, was a comparative study of two different dosing
protocols of radioactive iodine-131 in the treatment of hyperthyroidism. The study included 128
patients; these patients were randomly placed in the separate arms of the study. One group
contained 67 patients who received doses estimated by palpation alone, (100 µCi/ g of thyroid
tissue for diffuse goiter and 200µ Ci/ g of thyroid tissue for nodular goiter).3 There was a
maximum dose of 30 mCi (milicurie) set for these patients.3 The second arm of the study
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contained 61 patients and they were dosed with calculated method using palpation and 24-hour
uptake percentage.3 In this study most patients received antithyroid medication before the
therapeutic dose of iodine-131 was administered. These drugs were then discontinued at least 10
days before the date of therapy. Beta-blockers were not stopped for the therapy. The patients
were followed up to one year using a 5-point clinical symptom model as mentioned above and
biochemical studies to correlate.3 The results at one year of induced hypothyroidism in estimated
verses calculated were 48% to 52%, respectively.3 The results of persistent or recurrent
hyperthyroidism were 55% vs. 45%, respectively.3 The results for euthyroidism were 52% vs.
48%, respectively.3 With this data it can be observed a p-value of 0.185. The NNT for this study
was 10.
Table 3. Key Statistical Values of the RCT being reviewed.
p-value
0.05

Leslie et al.
(2003)
Pusuwan et
0.008
al. (2011)
Thientunyakit 0.185
et al. (2010)

CER
18%

EER
24%

RBI
86.7%

ABI
6%

NNT
17 patients

48%

30%

37.5%

-18%

-5 Patients

45%

55%

22.2%

10%

10 patients

CER= control adverse event, EER= experimental adverse event, RBI= relative benefit increase, ABI=
Absolute benefit increase, NNT= numbers needed to treat.

Pusuwan et al. 2011, conducted a prospective randomized study comparing the efficacy
of high and low dose iodine-131 treatment for hyperthyroidism. This particular study took 150
patients and randomly placed them into a high dose and low dose group.1 Any patients that were
taking antithyroid medication were taken off of the medication 5-7 days prior to the therapy.
The patient’s glad size was measured using a 24-hour uptake percentage. A calculation was used
with a formula of 150 µCi/g of thyroid tissue for the high dose arm and 100 µCi/ g of thyroid
tissue.1 The study used the theory that failed therapy was maintained or recurrent
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hyperthyroidism and successful treatment was defined as euthyroid state or hypothyroid state.
Patients were followed one year by clinical symptomatology were specifically evaluated for
nausea, heart failure and arrhythmias from increased metabolic activity and thyroiditis with
biochemical evaluation via TSH and T3/T4.1 The success rate at one year was 70% for the high
dose group and 52% for the low dose group with a p-value of 0.027.1 When doing statistical a
statistical analysis on the trial it was found to have a p-value of 0.008.1 The NNT was calculated
to be -5.
DISCUSSION
There have been limited studies done on the effectiveness of high versus low does
radioactive iodine-131 on patients with hyperthyroidism. Even though this has been the gold
standard therapy for over 50 years1, many debate the differences in dose determination. It is
thought that this form of therapy is safe and effective but the most appropriate dose remains
controversial when aiming to get a patient to a euthyroid state. However, maintaining
euthyroidism maybe an ineffective goal in managing patients with iodine-131 because a large
percentage of this population treated converts to hypothyroidism. The RCTs used considered
iatrogenic hypothyroidism a successful treatment of hyperthyroidism, but for many practioners
this is still argued as being unsuccessful. This is because hypothyroidism can be managed easily
and the replacement hormone is fairly inexpensive. However, many patients do not want the
burden of thyroid replacement hormone and periodic medicine management. In Leslie et al.
2003, and Thientunyakit et al. 2010, it was noted that the ability to predict the clinical outcome is
only about 60% and shows the difficulty in the decision to pick high or low dose therapy for any
given patient.2,3 In the trial done by Thientunyakit et al. 2010, the calculated dose and the
estimated high and low dose groups had surprising similar outcomes and proved the low ability
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to predict the clinical outcome of this procedure. The other studies carry clinically significant pvalues, showing if the patient would receive an adjusted low dose of radioactive iodine-131 they
have an increased chance of failed therapy and subsequently would remain hyperthyroid. This
would cause them to be clinically symptomatic following the 5-point scoring system and in need
further treatment and subsequently more radiation, time and cost to the patient. Another aspect of
clinical consideration is if you treat the patient and they in fact do become hypothyroid then they
will require thyroid replacement hormone to avoid harmful hypothyroid sequela. These
complications are also mentioned in the 5-point scoring system for hypothyroidism.
There are notable limitations in all three trials used in this review which demonstrate that
more research needs to be done to better assess the dosing methods of iodine-131. For example
all three trials had a low number of patients enrolled in the comparative studies.1,2,3 The ability to
have a large number study is difficult because of the nature of the data being collected. There are
theorized inherent risks of ionizing radiation; therefore, this limits the number of participants of
this type of analysis. Each study reported that most patients were on antithyroid medication for a
period of time before therapy. It is still unknown how much this can actually affect the uptake
and efficacy of iodine-131 in the destruction of thyroid tissue. This could cause changes in
patient preparation and outcome post-therapy. It is also mentioned that with different clinicians
there could be a difference in estimated gland size when the thyroid is palpated. This can change
dose amounts and cause outcome to vary as well. With these considerations in three RCTs
reviewed, there needs to be many more studies in the evaluation of dose calculation and amount
of iodine-131 that is used to treat hyperthyroidism.
As a final consideration, it is essential to follow patients with an iatrogenically induced
hypothyroid state. There needs to be close follow up and management of these patients. It is
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possible to have long term debilitation and sequela involved with hypothyroidism.3 Practioners
need to be diligent and manage this condition closely so the patient can live a full life without
comorbities caused by the iodine-131 therapy.
CONCLUSION
After reviewing all three trials in this selective EBM review, the evidence is inconclusive
and contradictory as to whether high or low dose radioactive iodine-131 is more effective in
treatment of hyperthyroidism. Each study gives different outcomes and statistical data to whether
high, low, adjusted or fixed doses are the best. The United States needs more research and
development in this area of medicine to better understand the clinical outcomes it holds. This is
evident with two of the studies being conducted in Thailand and the other being done in Canada.
This information indicates the need for future research on the best way to dose patients to
achieve positive outcome for the patient. The prognosis of patients with hyperthyroidism is good.
However, ongoing research should be considered to identify a way to lengthen the time patients
are in a euthyroid state. This will lower the chance of potentially harmful and unpleasant sequela
from recurrent hyperthyroidism or induced hypothyroidism. This can also cut down the annual
healthcare cost of retreatment courses, diagnostic tests, multiple office visits and thyroid
replacement hormone therapy.
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